Asterias Biotherapeutics, a biotechnology company dedicated to developing cell-based therapeutics, provided an update on how company’s ongoing Phase1/2a SCiStar designed to evaluate the safety and potential efficacy of AST-OPC1 in the treatment of severe cervical spinal cord injury.
In the update, Michael Mulroy, President and Chief Executive Officer stated “We are pleased to provide this update regarding our ongoing clinical trial of AST-OPC1 for the treatment of severe cervical spinal cord injuries in patients for whom there are no viable treatment options and a high unmet medical need…Results-to-date from Cohorts 3 and 4 continue to show a positive safety profile and suggest that AST-OPC1 cells are successfully engrafting in patients, which is consistent with the data from our extensive preclinical testing”.